[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Prader-Willi Syndrome (PWS) (Genetic Disorders) - Drugs in Development, 2021

March 2021 | 113 pages | ID: PBAC3A8C5C43EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Prader-Willi Syndrome (PWS) (Genetic Disorders) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome - Drugs in Development, 2021, provides an overview of the Prader-Willi Syndrome (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. PWS is due to lack of several genes on one of an individual’s two chromosome 15’s. In the majority of cases, there is a deletion. In remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15’s from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 4, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.

Prader-Willi Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prader-Willi Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prader-Willi Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (Genetic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Prader-Willi Syndrome (PWS) - Overview
Prader-Willi Syndrome (PWS) - Therapeutics Development
Prader-Willi Syndrome (PWS) - Therapeutics Assessment
Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
Prader-Willi Syndrome (PWS) - Drug Profiles
Prader-Willi Syndrome (PWS) - Dormant Projects
Prader-Willi Syndrome (PWS) - Discontinued Products
Prader-Willi Syndrome (PWS) - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Prader-Willi Syndrome (PWS), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Auris Medical Holding Ltd, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Benuvia Therapeutics Inc, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Beryl Therapeutics Inc, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Bioprojet SCR, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Carmot Therapeutics Inc, 2021
Prader-Willi Syndrome (PWS) - Pipeline by ConSynance Therapeutics Inc, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, 2021
Prader-Willi Syndrome (PWS) - Pipeline by GLWL Research Inc, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Helsinn Group, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Lipidio Pharmaceuticals Inc, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Neuracle Science Co Ltd, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Notitia Biotechnologies Co, 2021
Prader-Willi Syndrome (PWS) - Pipeline by OptiNose Inc, 2021
Prader-Willi Syndrome (PWS) - Pipeline by OT4B, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Rhythm Pharmaceuticals Inc, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Soleno Therapeutics Inc, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Taysha Gene Therapies, 2021
Prader-Willi Syndrome (PWS) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2021
Prader-Willi Syndrome (PWS) - Dormant Projects, 2021
Prader-Willi Syndrome (PWS) - Discontinued Products, 2021

LIST OF FIGURES

Number of Products under Development for Prader-Willi Syndrome (PWS), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


More Publications